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CHAPTER I 
 
INTRODUCTION 
 
Malaria 
Malaria is a significant cause of morbidity and mortality in the tropical world, 
accounting for more than 500,000 deaths annually while more than 2.4 billion people are at 
risk of infection.1 Most deaths occur in children under 5 years old in sub-Saharan Africa. It 
is endemic in 109 countries and is present in all continents except for Antarctica and 
Australia. It is characterized by high fevers and a flu-like illness. Malaria protozoan parasites 
belong to the genus Plasmodium and five out of 100 species in this genus are known to infect 
humans. In Plasmodium falciparum, P. vivax, P. malariae, and P. ovale the parasites are 
spread to people by infected female mosquitos. In P. knowlesi malaria is spread from 
monkeys to people, occurring mainly in South-East Asia.2 P. falciparum is responsible for 
99% of all malaria deaths, but is primarily found in Africa. P. vivax accounts for the second 
largest mortality and is primarily found outside of Africa.2 
Elimination of malaria is a worldwide effort that began in the early 1900s and 
continues to this day. Malaria has been eliminated in western nations but still plagues 
developing countries. In the 1940s, elimination in the United States was achieved by 
removing mosquito breeding sites, introducing water management, and mass spraying of 
insecticides. After this success, a global eradication program began in 1955. However, it 
mainly consisted of indoor residual spraying interventions with DDT and massive, 
nonspecific distribution of antimalarial drugs. Although some regions experienced 
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intermittent transmission reductions, over time transmittance resurged in the 1960s with 
most mosquitos developing widespread DDT and drug resistance.3  
Malaria control intensified in 1998 when the World Health Organization (WHO) 
launched the Roll Back Malaria Initiative. As a result of this initiative, malaria has been 
eliminated in 17 endemic countries, incidence of malaria has decreased by 41% globally 
since between 2000-2015, and mortality rates have declined by 62% globally between 2000 
and 2015.2  To achieve worldwide eradication, sustained elimination in all regions over an 
extended time period is required. In low-prevalence areas, there is an increased contribution 
to transmission from submicroscopic, often asymptomatic infections.4 In some regions, 
submicroscopic carriers can account for up to 80% of all malaria infections.5 These are 
undetectable with light microscopy and rapid diagnostic tests, the current tools to diagnose 
malaria in resource-limited settings. Although other technologies exist that are sensitive 
enough to detect submicroscopic infections, these are too complex or too expensive for 
point-of-care applications in resource-limited settings. Affordable, easy-to-use, and highly 
sensitive diagnostic tests suitable for resource-limited settings are needed if malaria 
eradication is to be achieved.  
 
Malaria Life Cycle 
During a blood meal, mosquitos transmit an infective sporozoite which travels 
through the blood and enters hepatocytes, where it begins to reproduce asexually. In P. vivax, 
the sporozoites may remain in a dormant, hypnozoite state for weeks or months. Hypnozoites 
are responsible for a waves of relapses typically characterized in P. vivax. In both P. vivax 
and P. falciparum, sporozoites will first develop into trophozoites and then into schizonts, a 
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process which lasts one to two weeks. Each schizont forms tens of merozoites which are 
released from the hepatocytes, enter the bloodstream and then invade red blood cells, 
initiating another asexual multiplication cycle.6 Within red blood cells, metabolism of the 
parasite is dependent on the digestion of hemoglobin. Heme is produced as a result of this 
digestion, which is toxic to the parasites. They convert heme into hemozoin, an insoluble, 
crystalline pigment. A fraction of merozoites mature into gametocytes, which freely circulate 
in the bloodstream and are taken up and ingested by mosquitos. Merozoites which do not 
mature to gametocytes will develop sequentially to trophozoites, then schizonts, and finally 
to merozoites again which ruptures the infected red blood cell. The release of these 
merozoites also releases toxins that cause fevers that repeat every 24-48 hours with the life 
cycle of the merozoites. After merozoites are released, they infect additional red blood cells. 
During the erythrocytic reproductive phase, parasite proteins are exported to the surface of 
the red blood cell which enable the infected cells to avoid immune responses and adhere to 
host cells and endothelium. A P. falciparum infected red blood cell will express P. 
falciparum erythrocyte membrane protein 1 (PfEMP1) on its surface, which can bind to 
receptors on blood vessel endothelium.7 Adherence to venules in the brain can cause 
congestion and impaired oxygen flow, leading to cerebral malaria and death. Furthermore, 
trophozoite and schizont stage parasites can sequester to the microvasculature of multiple 
organs including the heart, brain, liver, and placenta, causing multi-organ dysfunction. 
Adherence of P. falciparum infected red blood cells to the vasculature reduces the 
effectiveness of some diagnostic tests.4  Only young forms of the parasite are detected in 
peripheral blood samples. Sequestration is also synchronized, which leads to large parasite 
density fluctuations in and out of peripheral circulation. This can result in false-negative 
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results in microscopy and molecular tests due to a lack of detectable parasites and parasitic 
nucleic acids at the time of blood draw.4 
 
Treatment of Malaria 
Chloroquine is a chemotherapeutic agent first developed in the 1940s and was the 
first line of antimalarial treatment until its utility diminished in the 1990s due to drug 
resistance. It belongs to a class of quinoline antimalarial drugs, and the resistance of malaria 
to chloroquine also increased its resistance to other quinolone drugs. Their primary 
component is quinine, a complex aromatic compound first purified from cinchona bark to 
cure malaria in the early 1600s.8 Quinoline compounds inhibit the parasites’ conversion of 
digested hemoglobin into crystallized hemozoin, which increases free heme and has a toxic 
effect on the parasites.9 Chloroquine’s effect is so powerful that in the 1960s it was sold at 
low doses for many common ailments, and even as a food supplement. Its efficiency as an 
antimalarial agent has declined as an effect of its extensive overuse. 
Chloroquine resistance has prompted many countries to adopt a new line of 
artemisinin drugs. Artemisinin’s are a group of powerful drugs that are currently considered 
the standard for treating malaria, but its mechanism of action is currently unknown. One 
proteomics analysis has shown that artemisinin can covalently bind to 124 protein targets of 
the parasite, which disrupts its metabolic processes and causes parasite death.10 The WHO 
explicitly discourages the use of artemisinin monotherapy, which can cause point mutations 
in the parasitic genome leading to drug resistance. Combination therapies are used instead, 
which combine one artemisinin and one chloroquine based drug.  
Drug resistance is one of malaria’s greatest threats to achieving eradication. 
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Artemisinin resistance has been discovered in Cambodia and Thailand, and there are no 
alternative medications to effectively take its place.11 It is possible the resistance has 
developed to due widespread overuse of drugs. Fake drugs can be bought in endemic regions 
which contain lower levels of drugs, but not enough to kill the parasites.  
 
Nucleic Acid Amplification Tests 
   Clinical diagnosis is the least expensive method to detect malaria, but symptoms 
often overlap with other tropical diseases, which impairs its specificity. Diagnostic tools are 
needed to prevent indiscriminate use of anti-malarials for febrile patients, which can increase 
Figure 1.  Sensitivity versus simplicity of malaria detection technologies. Malaria 
eradication is confounded by submicroscopic parasite carriers with a minimum 
transmissable parasite density (MPD) between ~1-5 parasites/µL blood. Although 
NAATs can detect MPD carriers, they are too complex for resource-limited settings. 
NASBA: Nucleic acid based sequence amplification. LAMP: loop mediated isothermal 
amplification. PCR: polymerase chain reaction. ELISA: enzyme-linked immunosorbent 
assay. RDT: rapid diagnostic test.5, 12-14 
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anti-malarial drug resistance. The most common malaria diagnostic tools can be divided into 
nucleic acid amplification tests (NAATs), optical methods, and rapid diagnostic tests (RDTs) 
(Figure 1). NAATs are the most sensitive detection method, and can be divided into 
thermocyclic and isothermal amplification tests.15-17 Light microscopy and lateral flow 
assays (LFAs) are the primary, field implemented optical and RDT techniques, respectively.  
Virtually all NAAT methods can detect a minimum of 0.05-5 parasites/µL of blood.5 When 
compared to light microscopy as a reference standard, both thermocyclic and isothermal 
NAATs have sensitivity and specificity greater than 95%. Traditional polymerase chain 
reaction (PCR) is the most common thermocyclic NAAT and typically targets the 18s 
ribosomal RNA gene, mitochondrial DNA, and telomere repetitive element 2.5 Despite its 
sensitivity, PCR is normally used only in central laboratories or peripherally to resource 
limited settings since it requires thermocycling and a trained technician.  
Loop mediated isothermal amplification (LAMP) is a promising isothermal 
amplification test that can be implemented more easily in resource limited settings.18 
Isothermal amplification strategies generally require less system complexity than 
thermocyclers. The amplification products of LAMP are progressively larger DNA 
sequences that can precipitate out of solution and be visualized with fluorescence or 
turbidity. Although it does not require a thermocycler, it requires a constant heat source to 
maintain a temperature between 62-65°C. It is also prone to contamination and amplification 
of non-targeted DNA sequences, which has limited its application in field settings.19 Despite 
the sensitivity of NAATs, they are still primarily implemented outside of malaria endemic 
countries.  
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Light Microscopy 
The current gold standard of malaria diagnosis is light microscopy with Giemsa-
stained blood smears.20 It is inexpensive to perform, can differentiate malaria species, and 
quantify parasites. A Giemsa solution is composed of eosin and methylene blue. The eosin 
component stains the parasite nucleus red and methylene blue stains the cytoplasm blue. The 
stain is performed for two types of samples called thick and thin blood smears. In a thick 
blood smear, a drop of blood is stained and then viewed in a microscope at 10x or 20x 
objective lens to detect large parasites. A negative result can only be reported after at least 
200 oil immersion fields at 1000x magnification are examined. In a thin smear, the blood is 
spread across a microscope slide before examination. Thick smears are useful for identifying 
if parasites are present, while thin smears are useful to specify the malaria species. However, 
it can be difficult to distinguish between certain species. For example, P.malariae and P. 
knowlesi appear similar under a microscope and other methods must be used to distinguish 
between the two.21 Thick smears can detect parasitemia as low as 5 parasites/µL of blood, 
but tends to average between 50 and 100 for its optimal performance in the field.20  
Giemsa stains typically require 45 minutes from blood collection to the result. 
Although many alternative staining methods have been developed, acridine orange (AO) is 
notable since it is relatively inexpensive and results are available within a few minutes.22 AO 
binds to RNA and emits a red fluorescence from blue light excitation, and intraerythrocytic 
malaria parasites are particularly rich in RNA. However, it binds nonspecifically to RNA 
from all cell types, so a microscopist must be trained in distinguishing fluorescently stained 
parasites from other cells. Moreover, it can be especially difficult to differentiate between 
different parasite species. When compared against a Giemsa stain the AO method has a 
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sensitivity and specificity between 80-100% for high levels of parasitemia.22 However, a 
decrease in sensitivity is observed for parasite concentrations below 100 parasites/µL of 
blood. Similarly to a Giemsa stain, 100 fields under high magnification are usually examined 
to reach a conclusive negative result. Since the resultant signal is fluorescent, a microscope 
must be equipped with a halogen lamp and an appropriate light filter. 
 Light microscopy is effective at detecting high concentrations of parasitemia, which 
has been useful for a differential diagnosis of malaria from other tropical diseases. However, 
it cannot sensitively detect parasitemias at concentrations seen in asymptomatic individuals, 
which range from 1 to 100 parasites/µl of blood.23 Accurate diagnoses are dependent on the 
skill of the microscopist, and as a result there is significant variability in its sensitivity. The 
chance of a false negative increases with decreased experience and skill of the 
microscopist.20 It is also time consuming to identify parasites at low concentration densities 
that require a hundred or more fields of view to be examined. Hence, many alternative 
diagnostic tools have been developed to assist in identifying malaria in low-resource settings. 
 
Rapid Diagnostic Tests 
RDTs, mainly LFAs, are the primary tool to screen populations for malaria. They can 
be easily distributed to tertiary areas where remote clinics may not have laboratories. An 
LFA consists of a sample pad, conjugate pad, and absorbent pad overlapped with a 
nitrocellulose strip, all housed in a plastic backbone (Figure 2).24  Antibodies specific to the 
target biomarker are immobilized on a test line on the nitrocellulose strip. Liquid sample 
applied to the sample pad flows by capillary force towards the opposite end of the strip. 
Within the conjugate pad, the target biomarker is typically labelled with a gold nanoparticle 
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functionalized antibody.  As the sample flows through the nitrocellulose strip, the target 
biomarker is immobilized at the test line which forms a sandwich between the gold 
nanoparticle and the immobilized antibody, identical to a sandwich ELISA. Each individual 
immobilized antibody captures exactly one gold nanoparticle. Accumulation of gold 
nanoparticles at the test line causes a visible red color change due to surface plasmon 
resonance. Excess fluid is absorbed by the absorbent pad at the end of the LFA.25 Most 
malaria LFAs are specific to a Plasmodium species or to a target that is conserved across all 
species. The most commonly targeted antigen is histidine rich protein II (HRPII), specific 
for P. falciparum. Other commonly targeted antigens include P. falciparum-specific lactate 
dehydrogenase and specific pan-Plasmodium targets on lactase dehydrogenase as well as 
aldolase enzyme.26 HRPII readily diffuses into the plasma and can be detected at lower levels 
of parasitemia than panmalarial antigens. Recently, some P. falciparum strains have been 
found with the HRPII gene deleted, which has led to an increase in HRPII-specific false 
negative results.27 HRPII can also persist in the bloodstream for a month after effective 
therapy.28 Hence, HRPII-specific LFAs cannot be used to determine therapy effectiveness. 
LFAs are important for screening populations for malaria. They require minimal 
operator training, can be interpreted easily, and cost less than $1 per test. As a result, they 
are widely adopted in resource limited settings. The WHO recommends that all individuals 
suspected of malaria be screened with LFAs or light microscopy.2  At parasitemia of 1000 
parasites/µL or greater, LFAs have a sensitivity and specificity of 99% and 96%. However, 
at parasitemia below 100 parasites/µL, the sensitivity and specificity drop to 53.9% and 
between 37-70%.28 LFA performance is also affected by harsh temperature and humidity 
conditions. Its decreased performance at low parasitemia excludes LFAs as a viable option 
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to detect asymptomatic individuals. Furthermore, The WHO recommends a minimal 
standard of 95% sensitivity and 95% specificity for P. falciparum parasite densities of 100 
parasites/µL of blood. Hence, LFAs do not meet the current standards of malaria detection.28 
 
 
  
Figure 2. Lateral flow assay design.24 
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Assay Design 
 
 In an LFA, a target biomarker binds to a gold nanoparticle at a conjugate pad and 
flows unidirectionally on a nitrocellulose strip towards a test line via capillary flow. At the 
test line, the biomarker is captured by immobilized antibodies in a 1:1 ratio. If enough 
biomarker is captured at the test line, the immobilized gold nanoparticles will produce a color 
change due to surface plasmon resonance. In effect, the biomarker acts as a hook to “catch 
and release” gold nanoparticles from the conjugate pad to the test line. At low concentrations 
of biomarker, not enough gold nanoparticles are released at the test line to produce a visible 
signal. 
We propose a new design to enable “cyclic catch-and-release.” In this design, 
biomarker can move cyclically between a “catch” chamber and a “release” chamber. 
Reporter beads are captured by biomarker in the catch chamber and are eluted in the release 
chamber. The beads are transferred to the release chamber if and only if biomarker is present. 
In theory, the signal in the release chamber is amplified by N times x, where N is the number 
of cycles completed and x is the number of cycling biomarkers (Figure 3). 
We base this design from our previous work on self-contained extraction tubes and 
malaria biomarker concentration strategies.29-31 An extraction tube contains prearrayed 
processing solutions separated by surface tension air valves. Magnetic beads initially catch 
biomarker in a sample solution and are subsequently transferred into an elution chamber with 
an external magnet to release the biomarker. Extraction tubes are more suitable for low-
resource concentration of biomarker than alternative methods such as centrifuges because 
they are self-contained and easy to use. Extraction tubes to date have unidirectional 
movement of biomarker. Bidirectional movement of biomarker has not previously been 
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considered.  
 For malaria, the target biomarker for purification is histidine rich protein II (HRPII). 
HRPII consists of 34% histidine, and approximately 85% of its structure is comprised of 
AHH and AHHAAD motifs.32  Ni(II)nitrilotriacetic acid (NiNTA) chelation is a well-
established method of coordinating polyhistidine repeats, notably for isolation and 
purification of his-tagged proteins. A single NiNTA molecule coordinates to two adjacent 
histidines with micromolar affinity.32 NiNTA surface functionalized magnetic beads have 
been shown to purify and reconcentrate HRPII from blood. Concentrated HRPII can be 
added to HRPII specific LFAs, which improves their limit of detection 8-fold.33-34 
 We propose to initially test cyclic catch-and-release amplification to detect HRPII. 
In our strategy, we preload tubing with a sample chamber, a catch chamber, a wash chamber, 
and an imidazole-rich release-detect chamber (Figure 4). In the sample chamber, anti-HRPII 
surface functionalized magnetic beads capture HRPII. Next, the beads are transferred with 
an external magnet to the catch chamber containing NiNTA surface functionalized reporter 
Figure 3. Cyclic catch-and-release 
amplification. Colorimetric beads (green) are 
transferred from the left to the right chamber 
over N cycles if and only if biomarker (brown) 
is present. 
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beads. The HRPII captured by magnetic beads coordinate to and catch the NiNTA reporter 
beads. The magnetic beads are then shuttled cyclically forward and backward between the 
catch and release-detect chambers. This cyclic movement transfers the reporter beads from 
the catch chamber to the release-detect chamber if and only if HRPII is present. The objective 
of this thesis is to test the performance of this strategy to detect recombinant HRPII in a self-
contained prototype.  
 14  
CHAPTER II 
 
MALARIA DETECTION WITH CYCLIC CATCH-AND-RELEASE SIGNAL 
AMPLIFICATION 
 
Abstract 
At the onset of some infectious diseases, diagnostic biomarkers begin to circulate 
the bloodstream in low concentrations. Early detection of these biomarkers can improve 
treatment outcomes, prevent long-term complications, reduce transmissions, or screen for 
asymptomatic individuals. For malaria, eradication efforts have been confounded by an 
asymptomatic population, which cannot be diagnosed with current detection technologies 
such as light microscopy and lateral flow assays. We have developed a cyclic catch-and-
release amplification design to detect malaria biomarker histidine rich protein II (HRPII) 
based on our previous work on extraction tubes and malaria catch-and-release. In this 
design, HRPII surface functionalized magnetic beads cyclically transfer NiNTA surface 
functionalized reporter beads from a “catch” chamber to an imidazole-rich “release-detect” 
chamber. In theory, the signal in the release-detect chamber should be amplified by N times 
x, where N is the number of cycles performed and x is the number of captured HRPII. We 
first created a self-contained prototype using polyhistidine functionalized magnetic beads, 
and demonstrated cyclic, linear amplification of NiNTA beads in the release-detect 
reservoir. Experimental parameters of the test were then optimized in a 96 well plate with 
anti-HRPII antibody functionalized magnetic beads and recombinant HRPII. The self-
contained prototype was modified to incorporate the optimized parameters and antibody 
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functionalized beads. The final design achieved a limit of detection of 5 nM HRPII with a 
signal to noise ratio of 20. Overall, this study supports cyclic catch-and-release 
amplification as a feasible alternative for malaria detection.  
 16  
Introduction 
At the onset of some infectious diseases, diagnostic biomarkers begin to circulate the 
bloodstream in low concentrations. Early detection of these biomarkers can improve 
treatment outcomes, prevent long-term complications, reduce transmissions, or screen for 
asymptomatic individuals.35 For malaria, asymptomatic individuals frequently have parasite 
concentrations below the limit of detection of light microscopy, the gold standard of malaria 
detection.14, 20 Malaria eradication efforts have been confounded by submicroscopic carriers, 
which may contribute up to 80% of infections in an area depending on its transmission 
intensity.5 The detection limit of microscopy is in the order of 100 parasites/µL of blood, 
and parasitemias as low as 1-5 parasties/µL of blood can contribute towards malaria 
transmission.13-14  
Lateral flow assays (LFAs) are one of the most commonly implemented malaria 
diagnostic tests. Although they are easy-to-use and have simple visible output, they are too 
insensitive for eradication efforts. At parasitemias <100 parasites/µL of blood, the sensitivity 
and specificity of LFAs are 53.9% and between 37-70%, respectively.28 Its decreased 
performance at low parasitemia excludes LFAs as a viable option to detect asymptomatic 
individuals. Furthermore, the WHO recommends a minimal standard of 95% sensitivity and 
95% specificity for P. falciparum parasite densities of 100 parasites/µL of blood. Hence, 
LFAs do not meet the current standards of malaria detection.28 
In an LFA, a target biomarker binds to a gold nanoparticle at a conjugate pad and 
flows unidirectionally on a nitrocellulose strip towards a test line via capillary flow. At the 
test line, the biomarker is captured by immobilized antibodies in a 1:1 ratio. If enough 
biomarker is captured at the test line, the immobilized gold nanoparticles will produce a color 
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change due to surface plasmon resonance. In effect, the biomarker acts as a hook to “catch 
and release” gold nanoparticles from the conjugate pad to the test line. At low concentrations 
of biomarker, not enough gold nanoparticles are released at the test line to produce a visible 
signal. 
We propose a new design to enable “cyclic catch-and-release.” In this design, 
biomarker can move cyclically between a “catch” chamber and a “release” chamber. 
Reporter beads are captured by biomarker in the catch chamber and are eluted in the release 
chamber. The beads are transferred to the release chamber if and only if biomarker is present. 
In theory, the signal in the release chamber is amplified by N times x, where N is the number 
of cycles completed and x is the number of cycling biomarkers (Figure 3).  
We base this design from our previous work on self-contained extraction tubes and 
malaria biomarker concentration strategies.29-31 An extraction tube contains prearrayed 
processing solutions separated by surface tension air valves. Magnetic beads initially catch 
biomarker in a sample solution and are subsequently transferred into an elution chamber with 
Figure 3. Cyclic catch-and-release 
amplification. Colorimetric beads (green) are 
transferred from the left to the right chamber 
over N cycles if and only if biomarker (brown) 
is present. 
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an external magnet to release the biomarker. Extraction tubes are more suitable for low-
resource concentration of biomarker than alternative methods such as centrifuges because 
they are self-contained and easy to use. Extraction tubes to date have unidirectional 
movement of biomarker. Bidirectional movement of biomarker has not previously been 
considered.  
 For malaria, the target biomarker for purification is histidine rich protein II (HRPII). 
HRPII consists of 34% histidine, and approximately 85% of its structure is comprised of 
AHH and AHHAAD motifs.32  Ni(II)nitrilotriacetic acid (NiNTA) chelation is a well-
established method of coordinating polyhistidine repeats, notably for isolation and 
purification of his-tagged proteins. A single NiNTA molecule coordinates to two adjacent 
histidines with micromolar affinity.32 NiNTA surface functionalized magnetic beads have 
been shown to purify and reconcentrate HRPII from blood. Concentrated HRPII can be 
added to HRPII specific LFAs, which improves their limit of detection 8-fold.33-34 
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We propose to initially test cyclic catch-and-release amplification to detect HRPII. 
In our strategy, we preload tubing with a sample chamber, a catch chamber, a wash chamber, 
and an imidazole-rich release-detect chamber (Figure 4). In the sample chamber, anti-HRPII 
surface functionalized magnetic beads capture HRPII. Next, the beads are transferred with 
an external magnet to the catch chamber containing NiNTA surface functionalized reporter 
beads. The HRPII captured by magnetic beads coordinate to and catch the NiNTA reporter 
beads. The magnetic beads are then shuttled cyclically forward and backward between the 
catch and release-detect chambers. This cyclic movement transfers the reporter beads from 
the catch chamber to the release-detect chamber if and only if HRPII is present. Our objective 
is to test the performance of this strategy to detect recombinant HRPII in a self-contained 
prototype.  
  
Figure 4. HRPII detection with cyclic catch-and-release amplification. 
Antibody surface functionalized magnetic beads initially capture HRPII 
in a sample solution and are shuttled to the catch chamber with an 
external magnet. NiNTA reporter beads coordinate to HRPII in the 
“catch” chamber and are eluted by a high concentration of imidazole 
into the “release-detect” chamber. Catch-and-release is cyclic and 
mediated by the bidirectional shuttling of magnetic beads between the 
catch and release-detect chambers. The release-detect chamber signal is 
proportional to the total number of cycles, N, and the number of HRPII 
on the magnetic beads. 
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Materials and Methods 
Materials 
Dynabeads MyOne Streptavidin T1 magnetic beads, mean diameter 1 µm were 
purchased from ThermoFisher Scientific (cat# 65601). Anti-HRP2 antibody was purchased 
from Abcam (cat# ab9203). Recombinant HRPII (rcHRPII) with a GST fusion tag was 
purchased from CTK Biosciences (cat# A3000). RcHRPII without the fusion tag was 
obtained from PATH. Two fluorescent NeutrAvidin-labeled polystyrene beads, 1 µm in 
diameter were purchased from ThermoFisher Scientific: yellow-green with 
excitation/emission 505/515 (cat# 8776), and red with excitation/emission 580/605 (cat 
#8775). Biotin N-hydroxysuccinimide ester (biotin-NHS) was purchased from Sigma-
Aldrich (cat# B2643). Biotin-X-NTA was purchased from AAT Bioquest (cat# 3006). Biotin 
covalently attached to a six carbon spacer with terminal 8 sequential histidines 
(polyhistidine) was customized and purchased from GenScript. Biotin covalently attached to 
a six carbon spacer with a terminal glutamate was customized and purchased from 
GenScript.  
 
Synthesis of polyhistidine functionalized magnetic beads 
We developed polyhistidine surface functionalized magnetic beads as a simplified 
system of the antibody/HRPII magnetic beads. Dynabeads were washed three times with a 
magnetic rack and reconstituted with binding buffer (1x PBS with 0.01% Tween 20, pH 7.4), 
then incubated with the beads’ maximum binding capacity of polyhistidine at 400 pmol 
polyhistidine/mg beads for 30 minutes at 4°C on a laboratory rotisserie. Next, the beads were 
washed three times and reconstituted with binding buffer. Free biotin was mixed with the 
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beads at the beads’ maximum binding capacity of 1700 pmol biotin/mg of beads to block 
any unoccupied streptavidin sites, and the beads were incubated for 30 minutes at 4°C. The 
beads were washed three times with binding buffer and reconstituted with 1X PBS 0.01% 
BSA and 0.01% Tween 20, pH 7.4 and incubated for at least one hour at 4°C. After 
incubation, the beads were washed three times and reconstituted with 1x PBS 0.005% BSA 
and 0.01% Tween 20, pH 7.4, then stored at 4°C at a concentration of 1 mg/mL.  
 
 Synthesis of antibody functionalized magnetic beads 
Biotin-NHS in dimethyl sulfoxide (DMSO) was mixed with anti-HRPII antibody at 
a 6:1 molar ratio and gently vortexed for 30 minutes at room temperature. The reaction was 
quenched with 10% volume Tris, pH 7.4. DMSO was removed from the mixture following 
the instructions of a 7000 MW zeba spin desalting column (ThermoFisher Scientific, cat# 
89882). Dynabeads were washed three times with binding buffer. Biotinylated antibody was 
added to magnetic beads at the beads’ maximum binding capacity of 20 µg antibody/mg 
beads, and the beads were incubated for one hour in binding buffer at 4°C. The magnetic 
beads were washed three times and reconstituted with binding buffer. Free biotin was mixed 
with the beads at the beads’ maximum binding capacity of 1700 pmol biotin/mg of beads to 
block any unoccupied streptavidin sites, and the beads were incubated for 30 minutes at 4°C. 
The beads were washed three times with binding buffer and then reconstituted and blocked 
with 1x PBS 0.01% bovine serum albumin (BSA) and 0.01% Tween 20, pH 7.4 for at least 
one hour. The beads were washed three times with binding buffer and reconstituted with 1x 
PBS 0.005% BSA and 0.01% Tween 20, pH 7.4 and stored at 4°C at a concentration of 1 
mg/mL. 
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Synthesis of NiNTA fluorescent beads 
We surface functionalized 1 µm diameter fluorescent beads with NiNTA to serve as 
our reporter bead. We chose fluorescent rather than colorimetric beads for more accurate 
quantification. NeutrAvidin functionalized yellow-green polystyrene beads were washed by 
centrifugation (20,000 rcf, three minutes) three times and reconstituted with binding buffer. 
Biotin-X-NTA was added at the beads’ maximum binding capacity and incubated in the dark 
for one hour at 4°C on a laboratory rotisserie. The maximum capacity varied by lot. For lot 
1702573, the binding capacity was 2.0 nmol biotin-NTA/mg beads, and for lot 1756667 the 
binding capacity was 9.3 nmol biotin-NTA/mg beads. After incubation, the beads were 
washed two times and reconstituted with binding buffer, then mixed with free biotin at the 
beads’ maximum binding capacity at 2.0 or 9.3 nmol biotin/mg beads for 30 minutes at 4°C. 
After washing the beads three times with binding buffer, they were reconstituted in 0.1 M 
HEPES, 0.01% Tween 20 pH 7.4. Nickel chloride was added to the suspension in a 1:1 molar 
ratio of nickel to available NTA sites. The solution was incubated overnight. The beads were 
then washed three times and reconstituted with binding buffer, then stored at 4°C at a 
concentration of 1 mg/mL. 
 
Synthesis of glutamic acid fluorescent beads 
To monitor nonspecific charged interactions between more positively charged, 
histidine rich magnetic beads and more negatively charged NiNTA reporter beads, we 
developed a control reporter bead. The control reporter bead was developed to have a similar 
negative surface charge to NiNTA beads. We expected any nonspecific bead-bead 
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interactions to be dominated by charged interactions. NeutrAvidin functionalized red 
polystyrene beads were washed by centrifugation (20,000 rcf, three minutes) three times and 
reconstituted with binding buffer. Biotin-glutamate was added at the beads’ maximum 
binding capacity of 7.9 nmol biotin-glutamate/mg beads and then incubated in the dark for 
one hour at 4 °C on a laboratory rotisserie. The beads were washed two times and 
reconstituted with binding buffer, then mixed with free biotin at the beads’ maximum 
binding capacity of 7.9 nmol biotin/mg beads for 30 minutes at 4°C. The beads were then 
washed two times and reconstituted with binding buffer, then stored at 4°C at a concentration 
of 1 mg/mL. 
 
Test formats for catch-and-release implementation 
 We used three formats to investigate the properties inherent within cyclic catch-and-
release amplification. The first format was in a self-contained prototype device, described 
below. We tested the cyclic catch-and-release amplification using polyhistidine 
functionalized magnetic without optimizing the experimental conditions solely for proof-of-
concept. In the second format, we performed multiplexed studies in a 96 well plate for 
different experimental conditions to optimize our self-contained prototype for a limit of 
detection study. In our final test format, we used the optimized, self-contained prototype with 
antibody functionalized magnetic beads and determined a limit of detection.  
 
Description of the cyclic catch-and-release device prototype 
A self-contained prototype device was developed based a previous design from our 
laboratory (Figure 5).36-37 FEP tubing (1.6 mm inner diameter, 3.2 mm outer diameter, 
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purchased from Saint-Gobain, cat# TSFE14-0125-031-50) was housed between two 
grooved, rotating gears, one of which was press-fit to a stepper motor (Applied Motion 
Products, cat# HT23-597). The linear tubing contained prearrayed sample, catch, wash, and 
release-detect chambers separated by surface tension air valves. The motor was controlled 
through a ST5-Q stepper motor driver (Applied Motion Products) with commands using the 
Q programmer software. A program was created in Q so that the tube moved up and down 
in a repeated sequence. Two ¾” x ¾” x ¼” rectangular, neodymium magnets (K&J 
Magnetics, cat# BCC4) were fixed on a 3D printed magnet mount and placed N-S on 
opposite sides of the FEP tubing. This magnet design was chosen from our previous work to 
evenly distribute beads throughout the chambers during mixing.38 Moving the tubing up and 
down between the magnets transferred the magnetic beads from one chamber to another 
through the air valves while leaving the liquid in the chambers fixed in place. Mixing was 
performed in each chamber by rapidly accelerating the tubing up and down, causing the 
magnetic beads to escape the magnetic field and disperse throughout the chambers. Reporter 
bead fluorescence in the FEP tubing was measured with a Qiagen ESElog USB fluorescence 
detector with dual excitation and emission filters (Qiagen, cat#9002069). Yellow-green 
fluorescent beads were measured with a 470 excitation and 520 emission filter. Red 
fluorescent beads were measured with a 565 excitation and 625 emission filter. Fluorescence 
measurements were obtained sequentially in order of yellow-green first and red second. 
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Figure 5. Left: Cyclic catch-and-release self-contained prototype. Tubing is inserted from the bottom 
of the 3D printed components and moved up until the magnetic beads are centered between the two 
magnets. Signal amplification is performed by shifting the tube up and down which shuttles the 
magnetic beads between a catch and release-detect chamber. Right: Prototype design for a cyclic 
catch-and-release amplification tube. Sample containing magnetic beads, catch, wash, and imidazole 
release buffers are separated by air valves and held in place by capping each tube end with soft clay.  
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At the beginning of cyclic catch-and-release, the magnetic beads were located in the 
sample chamber. The beads were collected by moving the tube down at a motor speed of 
0.05 in/s (0.02 rps) so that the sample chamber was positioned in-between the two magnets. 
Then the tube was driven up at 0.05 in/s which moved the beads through an air valve and 
into the catch chamber. The beads were mixed by accelerating the tubing up and down 
rapidly with a final speed of 3.6 in/s (10 rps), which caused to beads to escape from the 
magnetic field. After one minute of incubation, the beads were collected, and the tube was 
moved up to transfer the beads into a wash chamber. In each wash step the beads were mixed 
by accelerating the tubing up and down. The beads were transferred through each surface 
tension valve by moving the tubing up at 0.05 in/s. After the final wash, the tube was moved 
up at 0.05 in/s until the beads were shifted to the end of the release-detect chamber. Then the 
tube was moved down to transfer magnetic beads back up through the wash steps until they 
were in the capture chamber for the next cycle. Cycles were repeated by continuously 
shuttling the magnetic beads back and forth between the catch and release-detect chambers 
in the sequence described above. Fluorescence of the release-detect chamber was measured 
while the magnetic beads were mixing in the catch chamber.  
 
Proof-of-concept of cyclic catch-and-release amplification in a simplified system 
In our first testing format, we performed proof-of-concept for cyclic catch-and-
release amplification using a simplified system in the self-contained prototype. Biotinylated, 
polyhistidine compounds were surface functionalized on streptavidin coated magnetic beads 
in place of antibodies. This was performed to exclude complex antibody/antigen binding 
effects during proof-of-concept analysis. 150 µg of polyhistidine functionalized magnetic 
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beads were concentrated into 50 µL of 1x PBS w/ 0.1% Tween 20, pH 7.4 to create a sample 
chamber. A catch chamber was created by adding 10 µg of NiNTA and 10 µg of glutamate 
reporter beads to 50 µL of binding buffer. The FEP tubing was preloaded with the 50 µL 
sample chamber, the 50 µL catch chamber, two 100 µL washes, and a 20 µL imidazole 
release-detect chamber, each separated by 12 mm air valves. The wash chamber consisted 
of 1x PBS with 0.1% Tween 20, pH 7.4. The elution chamber consisted of 1x PBS with 500 
mM imidazole, 300 mM NaCl, and 0.025% Tween 20, pH 8. 10 cycles of catch-and-release 
for three tubes were performed. Release-detect chamber fluorescence for the NiNTA and 
glutamate beads were quantified for each cycle. 
 
Catch-and-release optimization studies in a 96 well plate 
After demonstrating proof-of-concept, we optimized experimental parameters within 
96 well plates to test multiple catch-and-release systems simultaneously. Each well in the 
assay is a chamber in the tubing design. Optimization of experimental parameters was 
performed using antibody functionalized magnetic beads. 100 µL of antibody functionalized 
magnetic beads was washed three times with binding buffer, and then 500 µL of 10 nM CTK 
rcHRPII in binding buffer were added to the beads. Another batch of 100 µL of magnetic 
beads was mixed with 500 µL of binding buffer only to serve as a negative control in each 
optimization experiment. The beads were incubated for 30 minutes on a laboratory rotisserie. 
After incubation, the beads were washed three times with binding buffer and reconstituted 
with 500 µL of binding buffer. 
Optimization of reporter capture time was performed for a single cycle of catch-and-
release in 96 well, black, round-bottom plates (Costar #3792). The assay was initiated by 
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adding 1.25 µg of rcHRPII surface captured magnetic beads and 20 µg of yellow-green 
NiNTA fluorescent beads to 55 µL of binding buffer (containing 150 mM NaCl) to the first 
three wells in row 1 of the plate. The same number of negative control beads, NiNTA beads, 
and binding buffer were added to the next three wells in row 1. The final volume of the wells 
was 100 µL. The beads were mixed in solution using a VWR standard analog shaker (VWR 
International, cat# 89032-092) for 2.5 minutes at 500 rpm to suspend the beads in solution. 
The beads were then mixed for an additional 2.5, 5, or 10 minutes at 260 rpm. To prevent 
spillage of beads into adjacent wells, the plate was fixed on the shaker using wooden mounts. 
After mixing, magnetic beads were then pulled to the side of each well with a magnetic bead 
separation block. The supernatant was withdrawn and dispensed into row 2. A wash 
consisting of 100 µL PBS 0.1% Tween 20, pH 7.4 (wash buffer) was added to the magnetic 
beads in column 1 and mixing was performed for 2.5 minutes at 500 rpm. Subsequently, the 
first wash was removed, dispensed into row 3, and a second wash was added to row 1. Mixing 
was performed for 2.5 minutes.  After the second wash was removed and added to row 4, 
elution buffer consisting of 100 µL 500 mM imidazole, 300 mM NaCl, and 0.025% Tween 
20 at pH 8 was added to the magnetic beads. The beads were mixed for 2.5 minutes at 500 
rpm, and then for an additional 2.5 minutes at 260 rpm. The supernatant was removed and 
added to column 5, and then a third wash step was performed. Triplicates for 0 and 10 nM 
HRPII were performed in each plate and three plates were measured for each capture time. 
Fluorescence was measured in a BioTek Synergy HT plate reader with a 485/20 excitation 
and 530/25 emission filter immediately before mixing the third wash. 
The number of initial NiNTA beads was optimized by adding 5, 10, 20, or 40 µg of 
NiNTA beads to 1.25 µg of 0 or 10 nM HRPII-captured magnetic beads in row 1 of the plate. 
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Binding buffer was added so that the final volume of the wells was 100 µL with a salt 
concentration of 150 mM NaCl. The beads were mixed for 2.5 minutes at 500 rpm and then 
for 2.5 minutes at 260 rpm. All other steps were performed identically to the time 
optimization study. Triplicates were performed for each group within each plate. 
To optimize the reporter bead salt concentration, three binding buffers were created 
with 1x PBS, 0.01% Tween 20 at pH 7.4 with a salt concentration of 150, 300, or 450 mM 
NaCl. For each salt concentration, 1.25 µg of 0 or 10 nM HRPII-captured magnetic beads 
and 20 µg of NiNTA beads were added to 100 µL of each of the three binding buffers. 
Triplicates for 0 nM and 10 nM HRPII-captured beads were performed within each plate. 
The magnetic and fluorescent beads were mixed for 2.5 minutes at 500 rpm, and then for 2.5 
minutes at 260 rpm. All other steps were performed identically to the reporter capture time 
optimization study. 
  
Effects of catch chamber pH on NiNTA and glutamate bead release 
The HRPII surface captured on magnetic beads have a more positive charge density 
compared to the NTA on the reporter beads. Any charged, nonspecific interaction between 
the beads in the catch chamber will be influenced by pH. Hence, we performed multiplexed, 
optimization studies for catch chamber pH in a 96 well plate to determine how it influenced 
nonspecific binding of reporter beads to magnetic beads. Optimization was performed with 
polyhistidine functionalized magnetic beads. 5 µg of magnetic beads were mixed with 0.5 
µg of NiNTA beads and 0.5 µg of glutamate beads in 100 µL of binding buffer at pH 5, 7, 
8, or 9 in a single well, in triplicates. Magnetic and fluorescent beads were mixed for 2.5 
minutes at 500 rpm and then for another 2.5 minutes at 260 rpm on the VWR shaker. The 
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subsequent catch-and-release steps were performed identically to the reporter capture time 
optimization study. Yellow-green fluorescence of the catch, wash, and elution chambers 
were first measured with 485/20 excitation and 530/25 emission filters. Red fluorescence 
was measured immediately after with a 590/20 excitation and 645/40 emission filter.  
 
Limit of detection for HRPII in the self-contained prototype. 
 The limit of detection for cyclic catch-and-release detection of HRPII was 
determined in the self-contained prototype using the optimized parameters from above. 150 
µg of anti-HRPII antibody functionalized magnetic beads were washed three times and 
reconstituted with binding buffer in an Eppendorf tube. The supernatant was removed and 
500 µL of 0, 0.1, 0.5, 1, or 5 nM of rcHRPII (PATH) in binding buffer were added to the 
beads. This rcHRPII was used since it does not contain a GST tag and has a molecular weight 
of 35 kD, similar to native HRPII.26 The Eppendorf tube was placed on a laboratory rotisserie 
and incubated for 30 minutes. The beads were washed three times and reconstituted with 50 
µL of 1x PBS with 150 mM NaCl, 0.1% Tween 20, pH 8. In a separate Eppendorf tube, a 
catch chamber was created with 10 µL of NiNTA and 10 µL of glutamate reporter beads  
mixed with 30 µL of 1x PBS with 0.1% Tween 20, pH 8. A tube prototype was preloaded 
with the magnetic beads, catch chamber, four 50 µL wash chambers, and a 20 µL elution 
chamber sequentially. Adjacent chambers were separated with 12 mm air valves. Four wash 
chambers were utilized to reduce nonspecific carryover of reporter beads. Magnetic beads 
were mixed in the capture chamber for one minute. Cyclic catch-and-release amplification 
was performed for ten cycles using the program described previously.  
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Statistics 
Unless otherwise indicated, all error bars represent the mean +/- the standard 
deviation for a sample size of n=3. All tests for significance for multiple groups were 
performed with ANOVA. Significance was defined to be when the p-value for a comparison 
was p<0.05 at 95% confidence. The limit of detection (LOD) was defined as: 
𝐿𝑂𝐷 = 𝜎0 𝑛𝑀 + 3𝑆𝐷0 𝑛𝑀 
Where 𝜎0 𝑛𝑀 is the mean 0 nM control signal and 𝑆𝐷0 𝑛𝑀 is the standard deviation of the 0 
nM control signal. An experimental group achieved the limit of detection when its signal 
was greater than the LOD and significantly different than the 0 nM control. For studies using 
only NiNTA reporter beads, the signal to noise ratio was calculated as the ratio of the test 
concentration over the zero control. For studies with NiNTA and glutamate reporter beads, 
the signal to noise ratio was calculated as the ratio of NiNTA over the glutamate signal for 
each test concentration. 
  
 32  
Results 
Proof-of-concept of cyclic catch-and-release amplification in a simplified system 
 Cyclic amplification of NiNTA reporter beads in the release-detect chamber was 
approximately linear over 12 cycles (Figure 6). The slope of a linear fit indicated that 32,000 
NiNTA beads accumulated in the release-detect chamber each cycle. This corresponded to a 
capture ratio of 3 NiNTA beads for every 10,000 polyhistidine functionalized magnetic 
beads. The glutamate beads also accumulated in the release-detect chamber linearly at a rate 
of 600 glutamic beads/cycle, corresponding to a capture ratio of 3 glutamate beads for every 
500,000 magnetic beads. A total of 386,000 ± 91,300 NiNTA beads and 7,340 ± 2570 
glutamate beads accumulated in the release-detect chamber by the 12th cycle. The difference 
was significant with p<0.05 with 95% confidence using an unpaired t-test.  
 
  
Figure 6. Cyclic catch-and-release 
amplification with polyhistidine functionalized 
magnetic beads. Release-detect chamber 
fluorescence is plotted for each cycle. Specific 
reporter beads (NiNTA, black) are compared 
against nonspecific reporter beads (Glu, white). 
Signal to noise for each cycle is indicated in red 
triangles. 
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Catch-and-release optimization studies in a 96 well plate 
 Increasing the reporter bead capture time had no significant effect on signal to noise 
(Figure 7A). For 2.5, 5, and 10 minutes of capture time, the signal to noise ratio of a single 
cycle of catch-and-release were 19 ± 4.6, 25 ± 4.6, and 23 ± 6.0 respectively. At 5 and 10 
minutes, both specific and nonspecific release of NiNTA beads was observed to increase in 
the release-detect chamber when compared to 2.5 minutes. 2.5 minutes was the minimum 
possible time to automatically maintain suspension of the magnetic and reporter beads during 
capture in a 96 well plate. As a result, <2.5 min was chosen as our capture time for an 
optimized prototype design.  
Increasing the number of reporter beads in the initial capture chamber increased 
signal to noise only at the largest volume of beads tested (Figure 7B). There was no 
significant difference between 5, 10, and 20 µg of initial NiNTA reporter beads for a single 
cycle of catch-and-release, which had signal to noise ratios of 8.2 ± 2.1, 11 ± 3, and 12 ± 1.2 
respectively. An initial bead mass of 40 µg substantially (but not significantly) increased the 
signal to noise ratio to 21.5. However, the cost of 40 µg of NiNTA reporter beads is $3.60 
and the cost of 10µL is $0.80. Hence, 10 µL of reporter beads was chosen for the optimized 
prototype to minimize cost. 5 µL was not chosen due to the limited sensitivity of the Qiagen 
fluorimeter in the automated device.  
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Signal to noise was inversely proportional to reporter capture salt concentration 
(Figure 7C). The signal to noise ratios of 150, 300, and 400 mM NaCl in the catch chamber 
was 19 ± 4.6, 8.9 ± 4.6, and 7.9 ± 1.7 respectively. Increasing the salt concentration reduced 
the specific reporter bead signal in the release-detect chamber. Nonspecific release was 
reduced at lower rate than the specific signal for increased salt concentrations. 1x PBS was 
chosen for the optimized catch chamber buffer since 1x PBS contains 150 mM NaCl.  
 
  
A B C 
Figure 7. Optimization of reporter capture time, number of reporter beads, and reporter 
capture salt concentration for catch-and-release. A. Reporter capture time. B. Number 
of reporter beads. Signal to noise is plotted against the initial number of NiNTA beads 
in the catch chamber. N=2 C. Reporter capture salt concentration. The signal to noise 
is plotted against different NaCl concentrations in the catch chamber. 
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Effects of catch chamber pH on NiNTA and glutamate bead release 
The least nonspecific carryover of glutamate reporter beads was at catch chamber pH 
8 (Figure 8). At low pH of 5 and 7 the nonspecific signal was 21% and 31% of that total 
signal, and at pH 8 and 9 the nonspecific signal was 8% and 12% of the total signal, 
respectively. The total number of eluted reporter beads decreased from 128,000 at pH 7 to 
37,000 and 48,000 and pH 8 and 9. Hence, increasing pH of the catch chamber reduced the 
total signal generated in the release-detect chamber in a single cycle of catch-and-release, 
but it also increased the signal to noise. pH 8 had the greatest signal to noise ratio equal to 
8.7. A significant difference was achieved when comparing the signal to noise ratios of pH 
8 and 9 to pH 5 and 7. There was no significant difference when comparing pH 5 to pH 7 
and pH 8 to pH 9.  
 
  
Figure 8. Effects of pH on nonspecific 
carryover of reporter beads. Release-detect 
chamber signals of specific NiNTA reporter 
(dark grey) and nonspecific glutamic acid 
(light grey) reporter beads are plotted against 
the pH of the reporter catch chamber. Signal to 
noise is represented by the red bars. 
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Limit of detection for HRPII in an optimized, automated prototype 
The self-contained prototype was modified to incorporate the optimized parameters 
from the 96 well plate experiments. We initialized our experiments with 5 nM HRPII, 
slightly less than 10 nM HRPII from the plate optimization studies. In 10 cycles, the limit of 
detection was determined to be 5 nM HRPII using an ANOVA fixed-effects model, followed 
with pairwise t-tests. Signal to noise for 5 nM HRPII was significantly different than all other 
concentrations (Figure 9). The number of NiNTA reporter beads in the release-detect 
chamber after 10 cycles for 0, 0.1, 0.5, 1, and 5 nM HRPII were 150,000 ± 56,000, 140,000 
± 47,000, 160,000 ± 61,000, 250,000 ± 25,000, and 3,000,000 ± 380,000 beads. The number 
of glutamate reporter beads in the release-detect chamber were not significantly different 
between all concentrations. There were 280, 000 ± 36,000 glutamate reporter beads in the 
release-detect chamber for 5 nM HRPII, significantly less than the number of NiNTA beads 
in 5 nM HRPII and nearly equivalent to the final number of NiNTA beads in the 0 nM HRPII 
control. The rates of NiNTA reporter bead amplification for 0, 0.1, 0.5, and 1.0 nM HRPII 
were  12,000, 12,000, 14,000, and 22,000 beads/cycle respectively, and were not 
significantly different. The rate of amplification for NiNTA reporter beads in 5 nM HRPII 
was 300,000 beads/cycle. In comparison, the rate of amplification for glutamate reporter 
beads with 5 nM HRPII was 23,000 beads/cycle, nearly equivalent to the rate of NiNTA 
bead amplification in the 0 nM control.  
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Figure 9. HRPII limit of detection study in a self-contained, prototype 
device. Signal to noise is plotted against increasing concentrations of 
HRPII. 
* denotes limit of detection 
* 
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Discussion 
This study demonstrates the feasibility of cyclic catch-and-release amplification to 
detect HRPII in a self-contained prototype. Polyhistidine surface functionalized magnetic 
beads cyclically shuttle NiNTA reporter beads from a catch chamber to a release-detect 
chamber as shown by release-detect chamber signal amplification curves (Figure 6). 
Reporter bead concentration in the release-detect chamber increases approximately linearly 
after each cycle. Signal amplification for NiNTA reporter beads was significantly greater 
than the control glutamate reporter beads for the self-contained prototype using both 
polyhistidine and antibody-HRPII functionalized magnetic beads (Figures 6 and 9). With 
antibody functionalized magnetic beads the limit of detection was 5 nM rcHRPII. This is 
estimated to be equivalent to 10,000 parasites/µL of blood.39-40 To achieve malaria 
eradication in resource-limited settings, more sensitive diagnostic tools are needed to detect 
submicroscopic malaria carriers with parasitemias between 1-5 parasites/µL of blood.14 
Although our prototype currently has a higher limit of detection, we achieved our goal of 
demonstrating proof-of-concept for cyclic catch-and-release amplification.     
Based on our optimization studies, the following implementation was chosen for the 
final prototype design: 1) One minute of reporter bead capture time, 2) 10 µg of NiNTA 
beads and glutamate beads in the catch chamber, 3) catch chamber salt concentration of 150 
mM NaCl (1x PBS), and 4) catch chamber pH 8. Optimization studies were performed with 
10 nM rcHRPII, and for our final prototype our highest concentration tested was 5 nM 
HRPII. One minute of capture time is lower than the minimum time tested in the optimization 
study. In the optimization study, 2.5 minutes was the lowest time tested since it was both the 
minimum possible time to automate plate mixing, as well as the lowest time to sufficiently 
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disperse magnetic beads throughout the wells.  In the self-contained prototype, we observed 
significant reporter bead capture in as low as one minute of capture time. 
In the self-contained prototype, only one tube can be run at a time, and as a result a 
negative control cannot be run simultaneously to an experimental group. To monitor 
nonspecific carryover of reporter beads into the release-detect chamber, we developed 
glutamate surface functionalized reporter beads that we included in the catch chamber in the 
same concentration as NiNTA reporter beads. At pH 8, the charge densities of NTA and the 
C-terminus of glutamate are similar. Hence, the glutamate beads account for both 
nonspecific charged and carryover interactions between the reporter beads and more 
positively charged magnetic beads. In our limit of detection study, there is significantly more 
elution of NiNTA reporter beads than glutamate beads in the release-detect chamber at 5 nM 
HRPII (Figure 9), which provides evidence that the signal is not from nonspecific carryover.  
At 5 nM HRPII, we achieved a signal to noise ratio equal of approximately 20, while 
in our simplified, polyhistidine system we achieved a signal to noise ratio of approximately 
50. One reason for this phenomenon is that 300,000 polyhistidine peptides can functionalize 
to a single magnetic bead, while only 100,000 antibodies can functionalize to a magnetic 
bead. With our test conditions, our simplified system is equivalent to 400 nM HRPII, and 
we would expect a larger signal to noise ratio. Furthermore, our simplified system does not 
take into account complex antigen/antibody interactions. Our biotin-polyhistidine 
compounds functionalize more strongly to the streptavidin coated magnetic beads than the 
rcHRPII antigen binds to the antibody. Dissociation of antigen from the antibody during 
cyclic catch-and-release amplification could result in a reduced signal to noise ratio. 
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From Figure 9, it can be observed that there is a significant jump in signal to noise 
from 1 to 5 nM HRPII. It is plausible that under 5 nM HRPII there are not enough HRPII 
coordination sites available on the magnetic beads to catch reporter beads. Since the 
magnetic and reporter beads are extremely large compared to the HRPII that bridges them, 
many histidine and nickel interactions may be required within their contact radii to form a 
strong, dual complex. Otherwise, the reporter beads may be removed during wash steps or 
mixing. Each magnetic bead has approximately 100,000 antigen binding sites per bead, and 
hence in 5 nM HRPII there are approximately 15 HRPII available to be captured for every 
100 antibodies. Thus, about 15% of the total binding sites of the magnetic beads will be 
available to coordinate to nickel reporter beads in the catch chamber.  For sphere-sphere 
interactions, the contact radius a is equal to 1/R, where: 
1
𝑅
=
1
𝑅1
+
1
𝑅2
 
and R1 and R2 are the radii of the two intersecting spheres.41 With this equation, we 
estimated that for 5 nM HRPII approximately 1200 HRPII are surface captured on the 
magnetic beads within the contact radius. At 1 nM HRPII, only 239 HRPII are surface 
captured within the contact radius. This is limiting when compared to the number of available 
NiNTA sites in the contact radius of the NiNTA reporter bead, which exceeds 20,000 
NiNTA. It is unknown what the minimum number of coordination bonds are needed to form 
a stable, dual bead complex. 
Ideally, each histidine surface functionalized magnetic bead would capture at least 
one NiNTA reporter bead. Based on our release-detect data in the simplified system (Figure 
6), we observed that approximately 3 NiNTA reporter beads were captured for every 10,000 
magnetic beads and 3 glutamate reporter beads were nonspecifically captured for every 
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500,000 magnetic beads. Flocculation of particles have been extensively modeled.42 In the 
classical Smoluchowski model, it is assumed that all collisions lead to attachment. However, 
an energy barrier equal to the additive short-range forces of van der Waals attraction and 
electrostatic repulsion must be overcome for successful attachment. The magnetic and 
reporter beads in our study are comprised of a negatively charged polystyrene core and 
theoretically results in an increased energy barrier, which would reduce the amount of 
NiNTA bead capture. However, histidine functionalization of the magnetic beads should 
more strongly lower the energy barrier for magnetic beads to bind to NiNTA beads than to 
glutamate beads.  This matches with our results, where we observe a relatively low 
proportion of NiNTA beads captured per magnetic bead, but significantly more NiNTA bead 
capture than glutamate bead capture. 
In theory, signal amplification in the release-detect chamber should remain linear 
over many cycles. We observed that after 5-6 cycles signal amplification decreased (Figure 
6), and past 10 cycles amplification stagnated. We hypothesized that either the magnetic or 
the reporter beads were losing their functionality over time, which would cause less reporter 
beads to be captured in the catch chamber. To test this, magnetic beads and the catch 
chambers from experiments performed in Figure 6 were saved. When the magnetic beads 
were reused with new catch, wash, and release-detect chambers, they performed identically 
as using new magnetic beads (data not shown). However, when reused catch chambers were 
run with new magnetic beads, wash, and release-detect chambers, fluorescence elution was 
greatly diminished. Hence, it is possible that reporter release amplification decreases 
cyclically because of a loss in functionality of the catch chamber reporter beads. This loss in 
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functionality may be due to contaminants such as imidazole being introduced to the catch 
chamber. Further work is necessary to understand this phenomenon. 
  Cyclic catch-and-release amplification was automated using a computer and external 
software. We envision that the device can be modified to be more suitable for low-resource 
settings. For example, a pre-arrayed circular device can be wound up and activated similarly 
to an egg timer device. The device would rotate between stationary external magnets to 
transfer magnetic beads from one chamber to another. Colorimetric reporter beads would 
replace fluorescent reporter beads for field settings. After a fixed number of rotations, a 
diagnosis would be assessed with visual inspection of the release-detect chamber. 
 
Conclusion 
A cyclic catch-and-release amplification prototype was first developed with 
simplified reagents, which demonstrated cyclic amplification with a signal to noise ratio of 
50. The number of magnetic beads, number of reporter beads, catch buffer salt concentration, 
and catch buffer pH were optimized in a 96 well plate. The prototype was modified to 
incorporate the optimized parameters, which achieved a limit of detection of 5 nM HRPII. 
With further refinement, this catch-and-release design may offer an alternative to non-
amplification strategies employed in resource-limited settings. 
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APPENDIX A 
 
Computer code for the self-contained prototype 
 The following code is used for tube movement in the simplified system and for the 
results described in Figure 6. The catch-and-release tube starts in an initial position where 
the bottom meniscus of the sample chamber is at the top of the hole of the 3D printed magnet 
mount. The sample chamber contains preloaded magnetic beads. In this starting position, the 
catch chamber should be aligned in between the two magnets. The Qiagen fluorescence 
program is started and run simultaneously to the motor control Q program. The sensitivity 
of the fluorimeter may need to be adjusted in the Qiagen program so that the fluorescence 
signal does not max out during cycling. Comments are included in the Q programmer code 
below to describe each step. Multiple catch chamber measurements are measured in each 
cycle as a guide to know the tube position in the fluorescence output. 
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Q programmer computer code 
 
SEGMENT 1 
 
VE 0.02  Set velocity to 0.02 rps. Tube is in starting position 
FL -13500  Move tube down 13500 steps 
FL 9500  Move tube up 9500 steps – maneuver mag beads into catch chamber 
EP 0  Set current position to step#0 
SP 0  Set current position to step#0 
QX 2  Go to segment 2 
 
SEGMENT 2 
 
FP 2500  Move to step# 2500 
AC 10  Set acceleration to 10 
VE 10   
FP -1500   
FP 4500  Mix mag beads in catch chamber  
VE 0.5   
FP -23500  Measure catch chamber fluorescence 
WT 4.00   
FP -13000  Measure wash 1 fluorescence 
WT 4.00   
FP -23500  Measure catch chamber fluorescence 
WT 2.00   
FP 2000   
WT 4.00  Measure wash 2 fluorescence 
FP -23500   
WT 2.00   
FP 15700   
WT 4.00  Measure release-detect fluorescence 
FP -23500   
WT 2.00   
FP -1500   
QX 3 Go to segment 3 
 
SEGMENT 3 
 
VE 0.04   
FP 4500   
VE 0.02   
FP 9813  Move mag beads to wash 1 
VE 1   
FP 19000  Mix 
FP 9813   
VE 0.04   
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FP 20100   
VE 0.02  Move mag beads to wash 2 
FP 25982   
VE 1  Mix 
FP 35000   
FP 25982   
VE 0.04   
FP 35392   
VE 0.02   
FP 43139  Move mag beads to release-detect chamber 
FP 33708  Move mag beads to wash 2 
VE 1   
FP 24741  Mix 
FP 35708   
VE 0.04   
FP 24741   
VE 0.02   
FP 19527  Move mag beads to wash 1 
VE 0.04   
FP 8538   
VE 0.02   
FP 3437  Move mag beads to catch chamber 
QX 2  Go to segment 2  
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APPENDIX B 
 
Limit of detection in a 96 well plate 
A limit of detection study for cyclic catch-and-release amplification was conducted 
in a 96 well plate with the parameters characterized from the optimization study. A 10 µL 
10 µM aliquot of CTK rcHRPII was diluted to 500 µL aliquots of 100 pM, 1 nM, and 10 nM 
HRPII in Eppendorf tubes. 25 µg of antibody functionalized magnetic beads were added to 
each of the 500 µL rcHRPII aliquots. In addition, 25 µg of magnetic beads were added to 
500 µL of binding buffer only, which served as a negative control. The magnetic beads were 
incubated for 30 minutes on a laboratory rotisserie. After incubation, each group of beads 
were washed three times and resuspended in 500 µL of binding buffer. 100 µL from each 
group were added to separate wells of a 96 well plate in triplicates, and the supernatant was 
removed. 80 µL of binding buffer and 20 µL of NiNTA beads were added to each of the 
wells, in triplicates. A single cycle of catch-and-release was performed with 2.5 min of 
reporter capture time. Two washes were performed prior to elution and one was performed 
afterwards, as described in the optimization studies. Fluorescence was measured just before 
mixing with the third wash. After the third wash step, the second cycle was initiated by 
removing the third wash from row 1 and dispensing it into row 6. Then the catch chambers 
stored from row 2 were re-added to row 1 for another catch step. The second cycle was 
performed by repeating the catch, wash, and elution steps using the existing solutions in rows 
2-6. Seven cycles and were performed in total (Figure 10). An N of 3 was performed for 
each concentration. The limit of detection was determined to be 10 nM rcHRPII. 
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Figure 10. Cyclic catch-and-release 
amplification in a 96 well plate. A. NiNTA 
reporter bead fluorescence measured in the 
release-detect chamber after seven cycles of 
catch-and-release. * denotes limit of detection. 
B. Reporter bead fluorescence measured in the 
release-detect chamber at each cycle. NiNTA 
bead fluorescence is plotted against 1 nM 
HRPII and the negative control 0 nM HRPII. 
* 
A 
B 
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APPENDIX C 
 
Images of reporter bead capture 
250 µg of antibody functionalized magnetic beads were washed twice with binding 
buffer and then added to 500  µL of 5 nM rcHRPII from PATH. Another 250 µg of magnetic 
beads were mixed with 500 µL of binding buffer only to serve as a negative control.  The 
beads were incubated for 30 minutes on a laboratory rotisserie at 4°C. The supernatant was 
removed and the beads were washed three times with binding buffer, and then reconstituted 
with 500 µL of binding buffer. 100 µL of HRPII-magnetic beads and 100 µL of the negative 
control beads were added to separate wells in a 96 well plate. The supernatant was removed 
and a catch chamber consisting of 10 µg of NiNTA reporter beads in 100 µL of 1x PBS with 
0.1% Tween 20, pH 8 was added to the magnetic beads. One cycle of catch-and-release was 
performed according to the optimization studies with a reporter catch time of 2.5 minutes, 
except three washes were performed before elution. Just before the elution step, 25 µL of the 
third wash step containing the dispersed magnetic and reporter beads were obtained from 
both 5 nM and 0 nM HRPII groups. 5 µL of each were added into separate wells of an eight 
well chamber slide (ThermoFisher Scientific, cat# 154534) containing 300 µL of binding 
buffer. Fluorescence images were obtained with a Nikon Eclipse microscope and a FITC 
filter cube (DM mirror 505, excitor 480/40, barrier 535/50, cube# 96320) and Image Pro Plus 
software (Figures 11 and 12). In the software, an autoexposure time of 10s was applied for 
each picture taken.  
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Figure 11. NiNTA reporter bead capture with 5 nM HRPII magnetic beads. 
Green dots: NiNTA reporter beads. Brown dots: HRPII magnetic beads. 50x. 
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Figure 12. NiNTA reporter capture with 0 nM HRPII magnetic beads. Brown 
dots: HRPII magnetic beads. 50x. 
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APPENDIX D 
 
Nickel detection on NiNTA reporter beads  
ICP-OES 
 Nickel chelation of NTA functionalized reporter beads was characterized with 
inductively coupled plasma atomic emission spectroscopy (ICP-OES, Figure 13). 10 µg of 
NiNTA reporter beads (lot# 1756667) were centrifuged (14,000 rpm for 3 minutes) and 
washed three times with DI water. The supernatant was removed and 200 µL of 100 mM 
EDTA was added to the beads. The beads were incubated on a vortex shaker for five minutes, 
and then centrifuged for 3 minutes at 14,000 rpm. 100 µL of the supernatant was removed 
with care to not aspirate beads. The supernatant was added to 4.9 mL of 5% nitric acid. One 
1 ppm and one 10 ppm solution of nickel in 5% nitric acid were created as standards. ICP-
OES was then run according to the protocol below. 5% nitric acid served as a blank negative 
control. 
 No nickel was detected on the surface of the beads. This may be because the amount 
of nickel in the EDTA sample was close to the limit of detection for ICP-OES. For the test 
method described above, the final concentration of nickel in the nitric acid solution was 
calculated to be 2.2 µg/L, which approached the detection limit of 0.5 µg/L for nickel.  
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ICP-OES Instructions 
 
 Switch on power to the various components of the system.  
 Start the software and verify instrument configuration.  
 Install the pump tubing so the pump is ready to start automatically once the plasma 
is ignited. 
 Open feed of argon gas. 
 Get fresh DI water beaker to rest sample feed tube. 
 
 Ignite Plasma 
 New  Method 
 Default Aqueous 
 Define Elements  Wavelength 
o Ni 231.604 
o Cu 327.393 
o Zn 206.200 
o Co 228.616 
 Preference order indicates interference level 
 Choose state 
 Settings  30 sec delay time (to allow for feed to travel through tube to torch) 
 Spectrophotometer  3 replicates 
 No autosampler, No peak adjustment 
 Calibration 
o Set for each element 
o Check units 
 Results 
Figure 13. Nickel detection for NiNTA reporter beads with ICP-OES.  
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o No “start on new page” to compact results 
 Manual Analysis control open 
 Name results file. 
 Put intake tube in blank 
 Analyze blank (DI Water with 5% HNO3) 
 Analyze Standards lowest to highest 10 ppb is 0.01 ppm. 
 RF 1300 W Flow Rate 1.5 mL/min 
 Examine  See results, look at RSD 
o Move axis to the center of peaks and green arrows to the base and narrow. 
o Update method parameters, save and update after centering each axis. 
 Run one of the standards every ten samples to check for drift. 
 
 
TEM-EDX 
 
 Energy dispersive spectroscopy for transmission electron microscopy (TEM-EDS) 
was performed to determine if nickel was chelated to the surface of the NiNTA reporter 
beads (Figures 14 and 15). 0.1 µg of NiNTA reporter beads (lot#1756667) were washed 
twice and reconstituted with 100 µL of DI water. 20 µL of the beads were drop cast onto a 
copper mesh TEM grid and allowed to fully dry over 3-4 hours. EDX measurements were 
obtained by a FEI Tecnai Osiris. 
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Figure 14. TEM-EDX images of two NiNTA reporter beads. A. Carbon. B. Oxygen. 
The copper mesh grid had an oxygen signal near the beads. C. Nitrogen. D. Nickel. 
Carbon, oxygen, and nitrogen were from the polystyrene core and the streptavidin 
surface functionalization of the beads. 
A 
C 
B 
D 
Figure 15. TEM-EDX spectra of NiNTA reporter beads. The intense copper and 
medium silicon peaks were from the copper mesh grid. Cadmium peaks were a result 
of mesh contamination. The iron peak was noise from the instrument. 
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APPENDIX E 
 
Characterization of magnetic bead functionality 
Polyhistidine 
 
 Biotin-polyhistidine functionalization of magnetic beads was characterized with 
NiNTA horseradish peroxidase (HRP, ThermoFisher Scientific, cat# 15165), which was 
diluted 1:500 with 1x PBS, 0.1% Tween 20, pH 7.4. 25 µg of polyhistidine functionalized 
beads and 25 µg of biotin functionalized magnetic beads were added to separate wells of a 
clear, 96 well plate. The beads were washed twice with 1x PBS with 0.1% Tween 20, pH 7.4 
and then reconstituted with 100 µL of NiNTA HRP. After 10 minutes of incubation, the 
beads were washed twice and then reconstituted with 100 µL of ABTS/H2O2. Absorbance 
was read at 450 nm with a Synergy HT plate reader after a minimum incubation time of 10 
minutes (Figure 16). 
  
Figure 16.  Absorbance after the addition of ABTS/H2O2 
to NiNTA HRP/polyhistidine-bead complexes. 
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Anti-HRPII antibody 
 Anti-HRPII antibody functionalization of magnetic beads was characterized with 
goat anti-mouse IgG HRP (Sigma-Aldrich, cat# A0168). The anti-IgG HRP was diluted 
1:1000 in 1x PBS and 0.1% Tween 20, pH 7.4. 25 µg of antibody functionalized beads and 
25 µg of biotin functionalized beads were added to separate wells of a clear, 96 well plate. 
The beads were washed twice with 1x PBS with 0.1% Tween 20, pH 7.4, and then 
reconstituted with 100 µL of anti-IgG HRP. The beads were then incubated for a minimum 
of 10 minutes. Next, they were washed with 1x PBS with 0.1% Tween 20, pH 7.4, and then 
reconstituted with 300 µL of ABTS/H2O2. Color change was measured with the Synergy HT 
plate reader with 450 nm absorbance after 30 minutes (Figure 17). 
 
 
 
 
  
Figure 17. Absorbance after the addition of ABTS/H2O2 
to anti-IgG HRP/anti-HRPII bead complexes. 
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HRPII 
 
 HRPII conjugation to antibody functionalized magnetic beads was characterized with 
NiNTA HRP. The NiNTA HRP was diluted 1:250 in 1xPBS with 0.1% Tween 20, pH 7.4. 
100 µg of antibody functionalized magnetic beads were incubated with 0, 1, 10, or 100 nM 
of CTK rcHRPII in 500 µL binding buffer for 30 minutes. The beads were then washed three 
times with binding buffer. 25 µg of beads from each HRPII concentration were added to 
separate wells in a clear, 96 well plate and washed two more times with 1x PBS with 0.1% 
Tween 20, pH 7.4. The wash buffer was removed and the beads were then incubated with 
100 µL of NiNTA HRP for 10 minutes. The beads were washed twice and then 300 µL of 
ABTS/H2O2 were added to each well. After 30 minutes of incubation, absorbance at 450 nm 
was measured with a Synergy HT plate reader (Figure 18). 
 
  
Figure 18.  Absorbance after the addition of ABTS/H2O2 
to NiNTA HRP/HRPII-bead complexes. 
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APPENDIX F 
 
Zeta potential measurements of magnetic and reporter beads 
 Chemical groups on the surfaces of beads can vary in their charge and can influence 
nonspecific, charged interactions. Surface charges for magnetic and reporter beads were 
measured with a Malvern Nano ZS (Table 1). A universal dip cell shared by VINSE was 
obtained for these measurements. 5 µg of polyhistidine magnetic beads, NiNTA reporter 
beads, or glutamate reporter beads were added to separate disposable, polystyrene cuvettes 
containing 1 mL of 0.1x PBS (~15 mM NaCl), pH 8.  The beads were vortexed for 10 seconds 
prior to their addition in the cuvettes. A zeta potential SOP was created with the following 
settings: material: polystyrene latex; dispersant: water; general options – model – 
Smoluchowski; temperature: 25 °C; cell type: DTS1070 zeta dip cell; measurement: 
minimum runs = 10, maximum runs = 100, number of measurements = 3, and delay between 
measurements = 5 seconds. For each trial, the dip cell was first cleaned by sonicating the 
electrodes for 3-5 minutes, scrubbing the electrodes with pipe cleaner until the electrodes 
looked clean by visual inspection, and then air drying the electrodes. This cleaning process 
was repeated if necessary to clean the electrodes further. A cuvette containing beads was 
sonicated for 30 seconds, and the dip cell was added to the cuvette. The cuvette was then 
added to the zetasizer, and the protocol described above was run. After each series of three 
measurements the dip cell was cleaned as described above.  
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Beads Zeta Potential 
Polyhistidine magnetic beads -16 ± 0.95 
Glutamate reporter beads -23 ± 1.1 
NiNTA reporter beads -39.6 ± 1.5 
Table 1. Particle zeta potentials after surface 
functionalization. 
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APPENDIX G 
 
Reporter bead saturation in the release-detect reservoir 
We observed that the reporter release amplification in the release-detect reservoir 
began to decrease after 3-4 cycles (Figure 6). Chambers from experiments performed as 
described for the simplified system tests were saved. Saved polyhistidine magnetic beads 
were added to a self-contained prototype with new catch, wash, and release-detect chambers, 
and cyclic catch-and-release amplification was performed. We observed similar performance 
of cyclic catch-and-release compared to when new magnetic beads were used (Figure 19). 
Therefore, magnetic beads do not lose their reporter capture functionality over time. 
 
 
Figure 19. Effect of rerun magnetic beads on reporter 
release amplification. Polyhistidine magnetic beads run 
in a second cyclic catch-and-release experiment 
(orange) perform similarly to those run in only one 
experiment (blue). 
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 Next, catch chambers were saved from simplified catch-and-release assays that were 
run for one or two hours. They were added to a self-contained prototype containing new 
polyhistidine magnetic beads, new washes, and a new release-detect chamber. Cyclic catch-
and-release amplification was then performed for 12 cycles. We observed that catch 
chambers from the two hour assay resulted in decreased release per cycle than the expected 
values from the simplified system experiments (Figure 20). Catch chambers in the one hour 
assay performed similarly to the expected values. Hence, changes in the catch chamber over 
time may lead to a progressive decrease in reporter release amplification. This may be due 
to cycle-dependent contamination of the catch chamber, leaching of chelated nickel from the 
catch chamber reporter beads, or due to a subset of nonfunctional reporter beads that cannot 
be captured.  
  Figure 20. Effect of rerun catch chambers on reporter 
release amplification. Catch chambers used after two 
hours of cyclic catch-and-release (orange, n=1) resulted 
in decreased release per cycle than experiments 
performed in the simplified proof-of-concept study 
(grey, n=3). Catch chambers used after one hour (blue, 
n=1) performed similarly.  
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 It is possible that after performing cyclic catch-and-release for many cycles that the 
concentration of catch chamber reporter beads diminishes to a level which limits reporter 
capture. As a result, reporter release would decrease over time. We increased the starting 
concentration of reporter beads 10 fold to observe if the reporter release amplification 
decreased over time. After 12 cycles, we observed that reporter release amplification still 
decreased over time, despite a sufficient concentration of reporter beads in the catch chamber 
each cycle (Figure 21).  
  
Figure 21. Effects of increased reporter bead starting 
concentration on reporter release amplification. 
Reporter release amplification decreased cyclically 
after the reporter bead starting concentration was 
increased 10 fold. 
 63  
REFERENCES 
 
(1) Bousema, T.; Drakeley, C., Epidemiology and infectivity of Plasmodium falciparum 
and Plasmodium vivax gametocytes in relation to malaria control and elimination. 
Clinical Microbiology Reviews 2011, 24, 377-410. 
 
(2) WHO World Malaria Report; World Health Organization: Geneva, 2016. 
 
(3) Nájera, J. A.; González-Silva, M.; Alonso, P. L., Some lessons for the future from 
the global malaria eradication programme (1955-1969). PLoS Medicine 2011, 8 (1), 
1-7. 
 
(4) Tietje, K.; Hawkins, K.; Clerk, C.; Ebels, K.; McGray, S.; Crudder, C.; Okell, L.; 
LaBarre, P., The essential role of infection-detection technologies for malaria 
elimination and eradication. Trends in Parasitology 2014, 30 (5), 259-266. 
 
(5) Zimmerman, P. a.; Howes, R. E., Malaria diagnosis for malaria elimination. Current 
opinion in infectious diseases 2015, 28 (5), 446-454. 
 
(6) Miller, L. H.; Baruch, D. I.; Marsh, K.; Doumbo, O. K., The pathogenic basis of 
malaria. Nature 2002, 415, 673-679. 
 
(7) Rowe, J. A.; Claessens, A.; Corrigan, R. A.; Arman, M., Adhesion of Plasmodium 
falciparum-infected erythrocytes to human cells: molecular mechanisms and 
therapeutic implications. Expert Reviews in Molecular Medicine 2009, 11 (e16), 1-
29. 
 
(8) Schalkwyk, D. A. V.; Alphonse, C. L., History of Antimalarial Agents. eLS 2015, 
10.1002/9780470015902.a0003624.pub3. 
 
(9) Combrinck, J. M.; Mabotha, T. E.; Ncokazi, K. K.; Ambele, M. A.; Taylor, D.; Smith, 
P. J.; Hoppe, H. C.; Egan, T. J., Insights into the role of heme in the mechanism of 
action of antimalarials. ACS chemical biology 2013, 8 (1), 133-7. 
 
(10) Wang, J.; Zhang, C.-J.; Chia, W. N.; Loh, C. C. Y.; Li, Z.; Lee, Y. M.; He, Y.; Yuan, 
L.-X.; Lim, T. K.; Liu, M.; Liew, C. X.; Lee, Y. Q.; Zhang, J.; Lu, N.; Lim, C. T.; 
Hua, Z.-C.; Liu, B.; Shen, H.-M.; Tan, K. S. W.; Lin, Q., Haem-activated 
promiscuous targeting of artemisinin in Plasmodium falciparum. Nature 
Communications 2015, 6, 10111. 
 
(11) Enserink, M., Malaria's Drug Miracle in Danger. Science 2010, 328 (5980), 844-846. 
 
(12) PATH Malaria Diagnostics Technology Landscape: Enzyme Linked Immunosorbent 
Assays (ELISA) for Histidine Rich Protein 2 (HRP 2); PATH: Seattle, WA, 2014. 
 
(13) WHO, Policy brief on malaria diagnostics in low-transmission settings. 2014, 1-12. 
 64  
 
(14) Lindblade, K. A.; Steinhardt, L.; Samuels, A.; Kachur, S. P.; Slutsker, L., The silent 
threat: asymptomatic parasitemia and malaria transmission. Expert Review of Anti-
infective Therapy 2013, 11, 623-639. 
 
(15) Oriero, E. C.; Jacobs, J.; Van Geertruyden, J. P.; Nwakanma, D.; D'Alessandro, U., 
Molecular-based isothermal tests for field diagnosis of malaria and their potential 
contribution to malaria elimination. The Journal of antimicrobial chemotherapy 
2015, 70 (1), 2-13. 
 
(16) Vasoo, S.; Pritt, B. S., Molecular diagnostics and parasitic disease. Clinics in 
Laboratory Medicine 2013, 33, 461-503. 
 
(17) Roth, J. M.; Korevaar, D. A.; Leeflang, M. M.; Mens, P. F., Molecular malaria 
diagnostics: A systematic review and meta-analysis. Critical reviews in clinical 
laboratory sciences 2016, 53 (2), 87-105. 
 
(18) Han, E. T., Loop-mediated isothermal amplification test for the molecular diagnosis 
of malaria. Expert review of molecular diagnostics 2013, 13 (2), 205-18. 
 
(19) Morris, U.; Khamis, M.; Aydin-Schmidt, B.; Abass, A. K.; Msellem, M. I.; Nassor, 
M. H.; González, I. J.; Mårtensson, A.; Ali, A. S.; Björkman, A.; Cook, J., Field 
deployment of loop-mediated isothermal amplification for centralized mass-
screening of asymptomatic malaria in Zanzibar: a pre-elimination setting. Malaria 
Journal 2015, 14, 205. 
 
(20) Wongsrichanalai, C.; Barcus, M. J.; Muth, S.; Sutamihardja, A.; Wernsdorfer, W. H., 
A Review of Malaria Diagnostic Tools: Microscopy and Rapid Diagnostic Test 
(RDT). The American Journal of Tropical Medicine and Hygiene 2007, 77 (6), 119-
127. 
 
(21) McCutchan, T. F.; Piper, R. C.; Makler, M. T., Use of Malaria Rapid Diagnostic Test 
to Identify Plasmodium knowlesi Infection. Emerging Infectious Diseases 2008, 14 
(11), 1750-1752. 
 
(22) Keiser, J.; Utzinger, J.; Premji, Z.; Yamagata, Y.; Singer, B. H., Acridine Orange for 
malaria diagnosis: its diagnostic performance, its promotion and implementation in 
Tanzania, and the implications for malaria control. Annals of tropical medicine and 
parasitology 2002, 96 (7), 643-54. 
 
(23) Bousema, T.; Okell, L.; Felger, I.; Drakeley, C., Asymptomatic malaria infections: 
detectability, transmissibility and public health relevance. Nature Reviews 
Microbiology 2014, 12, 833-840. 
 
(24) Ngom, B.; Guo, Y.; Wang, X.; Bi, D., Development and application of lateral flow 
test strip technology for detection of infectious agents and chemical contaminants: A 
 65  
review. Analytical and Bioanalytical Chemistry 2010, 397, 1113-1135. 
 
(25) Moody, A., Rapid Diagnostic Tests for Malaria Parasites. Clinical Microbiology 
Reviews 2002, 15 (1), 66-78. 
 
(26) Jain, P.; Chakma, B.; Patra, S.; Goswami, P., Potential Biomarkers and Their 
Applications for Rapid and Reliable Detection of Malaria. BioMed research 
international 2014, 2014, 1-20. 
 
(27) Kumar, N.; Pande, V.; Bhatt, R. M.; Shah, N. K.; Mishra, N.; Srivastava, B.; Valecha, 
N.; Anvikar, A. R., Genetic deletion of HRP2 and HRP3 in Indian Plasmodium 
falciparum population and false negative malaria rapid diagnostic test. Acta tropica 
2013, 125 (1), 119-21. 
 
(28) Murray, C. K.; Gasser, R. a.; Magill, A. J.; Miller, R. S., Update on rapid diagnostic 
testing for malaria. Clinical Microbiology Reviews 2008, 21, 97-110. 
 
(29) Bordelon, H.; Adams, N. M.; Klemm, A. S.; Russ, P. K.; Williams, J. V.; Talbot, H. 
K.; Wright, D. W.; Haselton, F. R., Development of a low-resource RNA extraction 
cassette based on surface tension valves. ACS Applied Materials and Interfaces 2011, 
3, 2161-2168. 
 
(30) Adams, N. M.; Bordelon, H.; Wang, K. K. A.; Albert, L. E.; Wright, D. W.; Haselton, 
F. R., Comparison of three magnetic bead surface functionalities for RNA extraction 
and detection. ACS Applied Materials and Interfaces 2015, 7, 6062-6069. 
 
(31) Bordelon, H.; Ricks, K. M.; Pask, M. E.; Russ, P. K.; Solinas, F.; Baglia, M. L.; 
Short, P. A.; Nel, A.; Blackburn, J.; Dheda, K.; Zamudio, C.; Cáceres, T.; Wright, D. 
W.; Haselton, F. R.; Pettit, A. C., Design and use of mouse control DNA for DNA 
biomarker extraction and PCR detection from urine: Application for transrenal 
Mycobacterium tuberculosis DNA detection. Journal of Microbiological Methods 
2017, 136, 65-70. 
 
(32) Gulka, C. P.; Swartz, J. D.; Wright, D. W., Ni(II)NTA AuNPs as a low-resource 
malarial diagnostic platform for the rapid colorimetric detection of Plasmodium 
falciparum Histidine-Rich Protein-2. Talanta 2015, 135, 94-101. 
 
(33) Davis, K. M.; Swartz, J. D.; Haselton, F. R.; Wright, D. W., Low-resource method 
for extracting the malarial biomarker histidine-rich protein II to enhance diagnostic 
test performance. Analytical chemistry 2012, 84 (14), 6136-42. 
 
(34) Ricks, K. M.; Adams, N. M.; Scherr, T. F.; Haselton, F. R.; Wright, D. W., Direct 
transfer of HRPII-magnetic bead complexes to malaria rapid diagnostic tests 
significantly improves test sensitivity. Malaria Journal 2016, 15, 399. 
 
(35) Banoo, S.; Bell, D.; Bossuyt, P.; Herring, A.; Mabey, D.; Poole, F.; Smith, P. G.; 
 66  
Sriram, N.; Wongsrichanalai, C.; Linke, R.; O'Brien, R.; Perkins, M.; Cunningham, 
J.; Matsoso, P.; Nathanson, C. M.; Olliaro, P.; Peeling, R. W.; Ramsay, A., 
Evaluation of diagnostic tests for infectious diseases: general principles. Nature 
Reviews Microbiology 2006, 4, S21-S31. 
 
(36) Russ, P. K.; Karhade, A. V.; Bitting, A. L.; Doyle, A.; Solinas, F.; Wright, D. W.; 
Haselton, F. R., A Prototype Biomarker Detector Combining Biomarker Extraction 
and Fixed Temperature PCR. Journal of laboratory automation 2016, 21, 590-8. 
 
(37) Creecy, A.; Russ, P. K.; Solinas, F.; Wright, D. W.; Haselton, F. R., Tuberculosis 
Biomarker Extraction and Isothermal Amplification in an Integrated Diagnostic 
Device. Plos One 2015, 10, 1-14. 
 
(38) Scherr, T. F.; Ryskoski, H. B.; Doyle, A. B.; Haselton, F. R., A two-magnet strategy 
for improved mixing and capture from biofluids. Biomicrofluidics 2016, 10, 024118. 
 
(39) Gulka, C. P.; Swartz, J. D.; Trantum, J. R.; Davis, K. M.; Peak, C. M.; Denton, A. J.; 
Haselton, F. R.; Wright, D. W., Coffee rings as low-resource diagnostics: detection 
of the malaria biomarker Plasmodium falciparum histidine-rich protein-II using a 
surface-coupled ring of Ni(II)NTA gold-plated polystyrene particles. ACS applied 
materials & interfaces 2014, 6 (9), 6257-63. 
 
(40) Trantum, J. R.; Wright, D. W.; Haselton, F. R., Biomarker-mediated disruption of 
coffee-ring formation as a low resource diagnostic indicator. Langmuir: the ACS 
journal of surfaces and colloids 2012, 28, 2187-93. 
 
(41) Hanaor, D. A. H.; Gan, Y.; Einav, I., International Journal of Solids and Structures 
Contact mechanics of fractal surfaces by spline assisted discretisation. International 
Journal of Solids and Structures 2015, 59, 121-131. 
 
(42) Thomas, D. N.; Judd, S. J.; Fawcett, N., Flocculation modeling: a review. Water 
Research 1999, 33 (7), 1579-1592. 
 
 
